Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110

Benzinga Newsdesk www.benzinga.com Positive 90.8%

Neg 0% Neu 0% Pos 90.8%

Citizens analyst Jason N. Butler maintains Cytokinetics (NASDAQ:CYTK) with a Market Outperform and raises the price target from $105 to $110.